Table 14.

—[Sections 4.1.1-4.3.5] Six to Twelve Months vs One Month of Clopidogrel Plus Aspirin Following PCI With Placement of BMS^89-92

Outcomes	Participants (Studies), Follow-up	Quality of the Evidence (GRADE)	Relative Effect (95% CI)	Anticipated Absolute Effects Over 6-9 mo
				Risk With 1 mo Clopidogrel + Aspirin	Risk Difference With 6-12 mo Clopidogrel + Aspirin (95% CI)
Total mortalitya	3,390 (3 RCT), 6-12 mo	Low due to risk of biasb and imprecisionc	RR 0.73 (0.48-1.13)	28 per 1,000d	No significant difference; 8 fewer per 1,000 (from 15 fewer to 4 more)
MI nonfatal events	4,852 (3 RCTs), 6-12 mo	Moderate due to risk of biasa	RR 0.66 (0.50-86)	28 per 1,000d	9 fewer per 1,000 (from 14 fewer to 4 fewer)
Stroked	2,194 (2 RCTs), 6-12 mo	Low due to risk of biasa and imprecisionc	RR 0.46 (0.16-1.32)	10 per 1,000d	No significant difference; 5 fewer per 1,000 (from 8 fewer to 3 more)
Major extracranial bleede	5,052 (3 RCTs), 6-12 mo	Low due to risk of biasa and imprecisionc	RR 1.17 (0.86-1.60)	50 per 1,000d	No significant difference; 8 more per 1,000 (from 7 fewer to 30 more)

See Table 1-3 legends for expansion of abbreviations.

^aFatal bleeding events not reported.

^bBernardi et al⁹² and Pekdemir et al⁹⁰ were not blinded, and there was no placebo control; Bernardi et al stopped early for benefit. The Akbulut et al⁹³ design was unclear (no mention of randomization, but the Health Technology Assessment report referred to it as randomized). Mehta et al⁸⁹ had variable follow-up.

^cCIs include important benefit and harm.

^dControl group risk estimates derived from rates in subjects treated with dual antiplatelet therapy for 1 mo in included trials.

^eMajor bleeding not stratified by type of bleed; unclear whether major bleeding included any fatalities.